Ibandronate belongs to the bisphosphonate group of compounds which act specifically on bone.

Ibandronate 1mg/1ml, 3mg/3ml are indicated for the treatment and prevention of osteoporosis.

Ibandronate 2mg/2ml, 6mg/6ml are indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases and for the treatment of tumour-induced hypercalcaemia with or without metastases.
Active ingredient Pharmaceutical form Package Therapeutic target
  • Ibandronate IV
  • Concentrate for Sol. for Inf.
  • 1mg/1ml
  • 2mg/2ml
  • 3mg/3ml
  • 6mg/6ml
  • Bone Metabolism-Osteoporosis

Other products in "International"